Background
Multiple sclerosis | Myasthenia gravis | |
---|---|---|
Similarities | ↑ Th1 and Th17 cells [24] ↑ IL-1, -6, -17, IFN-γ, and TNF-α [26] Treg-related genetic polymorphisms (IL-2 signaling, CD25, CD127) [55] ↑ CXCR5 expression, correlates with disease [34] Clonally expanded B cells in thymus [33] ↓ Tr1 and IL-10 [27] ↑ Fas expression on Tregs [104] | ↑ Th1 and Th17 cells [23] Treg-related genetic polymorphisms [56] ↓ Recent thymic emigrants in blood [28] ↑ CXCR5 expression, correlates with disease [34] Clonally expanded B cells in thymus [33] ↓ Expression of FoxP3 and IL-10 on Tregs [28] ↑ Fas expression on Tregs [13] |
Differences | Thymectomy not beneficial [31] Macrophage cell-mediated damage [96] Can be treated via IFN-1 (beta) [12] | Thymectomy Beneficial [197] Antibody-mediated damage [39] Can be induced via IFN-1 (alpha) [42] |
Main text
Implications of dysregulated Tregs in MS and MG
Relevant Treg subsets and suppression mechanisms
Treg dysfunction in MS pathology
Treg migratory receptor dysregulation may have implications in MS
Therapeutics for multiple sclerosis which restore Treg abnormalities
Therapeutic modality | Intended Treg augmentation | Approach | Outcome | Reference |
---|---|---|---|---|
IL-10 | Upregulate Tr1, increase Tregs through DC modulation | EAE (MOG 1-125) Dark Agouti rats. pcDNA IL-10 Gene therapy on day 0 and 3 | ↓ clinical score ↓ sensory loss ↓ microglial/ macrophage and astrocyte activation | [143] |
IL-35 | Induction of iTr35 | EAE (MOG 35-55) C57BL/6. Adoptive transfer of iTreg induced with rIL-35 | ↓ clinical score ↑ life span ↑ iTr35 | [80] |
Bifunctional Peptide Inhibitors | Inhibit CD28 co-stimulation to promote CTLA-4 co-stimulation | EAE (MOG 35-55) C57BL/6. Injection of B7AP-PLP (anti-CD28 linked to PLP; 100 nmol) on days 4, 7, and 10 | No clinical signs ↓ change in weight ↓ IL-6,-17 ↑ IL-2, -4, -5 | [155] |
IDO Metabolite | Increase Tregs, increased CCL2-mediated migration to CNS | EAE (MOG 35-55) C57BL/6. 3-HAA (downstream IDO metabolite) treatment daily | ↓ clincal Signs ↓ disease peak ↑ FoxP3+ Tregs ↓ IL-17, IFN-gamma | [110] |
CXCL11 | Increase Tr1 migration to CNS, increase IL-10 expression, polarize Tr1 | EAE (MOG 35-55 and PLP129-151) in C57BL/6 and SJL/j mice, respectively. CXCL11-IgG every other day and adoptive transfer of CD4+ cells from CXCL11-IgG treated EAE SJL/j mice | ↓ clinical score ↓ histological score Prevented relapse ↑ Tr1 ↓ IFN-gamma, IL-17 | [122] |
IL-27 | Proliferation of Tr1, upregulate CXCR3 on FoxP3 Tregs for migration to CNS | EAE (MOG 35-55) C57BL/6. Adoptive transfer of CD4+ cells treated with MOG, IL-12, and IL-27 (control: MOG and IL-12) | ↓ clinical score ↑ Tr1 | [154] |
WT C57BL/6 J. Injection of IL-27 DNA plasmids | ↑ CXCR3 on Tregs and not Teff | [124] | ||
Emperically supported treatments using EAE and other experimental data | ||||
OX40L Jagged-1 Co-treatment | Selectively expand Tregs in TCR-independent manner, activate CD46 for induction of Tr1 | EAE (MOG 35-55) C57BL/6. Jagged1-Fc on days 0, 2, 4, 6, 8 | ↓ clinical scores ↓ disease peak ↑ IL-10, -4 | [159] |
EAE (PLP 139-151) SJL/j. Alpha OX40 agonist on days 10, 12, and 14. | ↓ clinical scores ↑ Tregs ↑ IL-2, -6, -17, and IFN-g in the CNS | [167] | ||
Site-specific CCL17 Injection | Selectively recruit Tregs to neuroinflammatory sites via CCR4 | EAE (MOG 35-55) C57BL/6. IL-4 gene therapy injection into cisterna magna on day of onset (12-16 days) | ↓ clinical scores ↑ IL-4 ↑ CCL17 ↑ Tregs in brain and spinal cord | [119] |
Ex vivo human Treg transmigration assay with porcine aortic endothelial cells coated with CCL17 | ↑ Treg adhesion ↑ Treg transmigration via CCR4 | [172] |
Administration of interleukins
Bifunctional peptide inhibitors
OX40L/Jagged-1 co-treatment
Migratory modulation
Treg dysfunction coincides with autoantibody production in myasthenia gravis
What recent research reveals about Treg homing to germinal centers in myasthenia gravis
Anti-inflammatory therapeutics for myasthenia gravis which augment Treg function
GM-CSF
Therapeutic modality | Intended Treg augmentation | Approach | Outcome | Reference |
---|---|---|---|---|
GM-CSF | Expand functional Tregs via Tolerogenic DCs | 77-year-old male with myasthenia crisis untreated with conventional treatments. GM-CSF 750 μg daily for 2 days, then 250 μg daily for 3 days, then 5 more 250 μg doses daily in week 7–8 | Cessation of myasthenic crisis ↑ strength weaned from ventilator | [198] |
EAMG (tAChR) in C57BL/6. GM-CSF daily on days 0–9 and 37–41 | ↓ clinical score ↓ weight loss ↓ anti-AChR Ab ↑ IL-10, -4, FoxP3 ↓ IFN-g | [200] | ||
IL-2/mAb complexes | Activate peripheral Treg, activate and TFR in GC to suppress TFH and B cells, increase Treg migration to GC | EAMG (tAChR) in thymectomized C57BL/6. IL-2 complexes twice weekly | ↓ clinical score ↓ autoantibodies ↓ CD19 cells ↑ TGF beta ↓ IFN-g | [189] |
Emperically supported treatments yet to be used in EAMG pre-clinical models | ||||
OX40L Jagged-1 Co-treatment | Selectively expand functional Tregs in TCR-independent manner, modulate CD46 Treg stimulation | EAMG (tAChR) C57BL/6. Adoptive transfer of Tregs from GM-CSF treated EAMG mice into EAMG mice | ↓ clinical score ↓ auto antibodies ↑ AChR content | [67] |
Experimental autoimmune thyroiditis (via murine thyroglobulin) CBA/j. Adoptive transfer of OX40L + Jagged1+ from GM-CSF treated bone marrow DCs (control: non treated and single OX40L positive) | ↓ pathology in double positive only ↑ Treg in double positive only | [157] | ||
TGF-beta | Induce iTregs | Lupus-prone mice (NZB/NZW F1). Adoptive transfer of CD4 + CD62L + CD25-CD44low cells stimulated with anti-CD3 and anti-CD28 in presence of IL-2 and TGF-beta | ↓ multiple auto antibodies | [208] |
Ex vivo human MG peripheral blood mononuclear cells. Stimulated with TGF-beta | ↓ mRNA for IFN-gamma, IL-4, -6, TNF alpha, TNF beta Suppressed AChR-reactive IFN-gamma and IL-4 secreting cells | [209] |